Patent US3937663A successfully refreshed from Google Patents.
Patent US5069908A successfully refreshed from Google Patents.
US5069908A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Crosslinked hydrogel and method for making same
Assignee: Maxxim Medical Inc
•
Filing: 1990-06-06
•
Granted: 1991-12-03
•
Expires: 2010-06-06
Abstract
Abstract A chemically crosslinked hydrogel includes an active ingredient for transdermal transport selected from the group of lidocainehydrochloride, hydrocortisone, menthol, and methyl salicylate and utilizes as a crosslinking agent an aluminum acetate, which is a polyvalent salt, which renders the resulting hydrogel electrically conductive with a resistance of less than 10,000 ohms per linear centimeter.
Inventors
- 👤 Ernest J. Henley
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 03:46
CPC Classifications
A; A61; A61N; A61N1/00; A61N1/02; A61N1/04; A61N1/0404; A61N1/0408; A61N1/0428; A61N1/0448; A61K; A61K47/00; A61K47/30; A61K47/36; A61K47/38; A61K9/00; A61K9/0002; A61K9/0009; A61K9/0012; A61K9/0014; A61F; A61F13/00; A61F2013/00361; A61F2013/00902; A61F2013/00919; A61F13/15; A61F13/53; A61F2013/530481; A61F13/84; A61F2013/8476; A61F2013/8479
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
108 words
A crosslinked hydrogel for use in transcutaneous electrical nerve stimulation and iontophoresis to provide transdermal delivery of an active ingredient comprising: (a) an active ingredient selected from the class of lidocainehydrochloride, hydrocortisone, menthol or methyl salicylate; (b) a crosslinking agent, aluminum acetate in a quantity of about 0.1% to about 0.5% by weight to provide ionic conductivity in said hydrogel; (c) water; (d) an emulsifier selected from the class of propyleneglycol, lanolin, stearic acid or ethyl alcohol; and (e) carboxymethylcellulose in an amount of between 1.1% to 1.7% by weight, wherein said hydrogel is characterized by having an electrical resistance of less than 10,000 ohms per linear centimeter.
Claim 2
Dependent Claim
108 words
A crosslinked hydrogel for use in transcutaneous electrical nerve stimulation and iontophoresis to provide transdermal delivery of an active ingredient comprising: (a) an active ingredient selected from the class of lidocainehydrochloride, hydrocortisone, menthol or methyl salicylate; (b) a crosslinking agent, aluminum acetate in a quantity of about 0.1% to about 0.5% by weight to provide ionic conductivity in said hydrogel; (c) water; (d) an emulsifier selected from the class of propyleneglycol, lanolin, stearic acid or ethyl alcohol; and (e) carboxymethylcellulose in an amount of between 1.1% to 1.7% by weight, wherein said hydrogel is characterized by having an electrical resistance of less than 10,000 ohms per linear centimeter.
Claim 3
Dependent Claim
23 words
A crosslinked hydrogel as defined in claim 1 wherein said hydrogel contains less than about 4% by weight lidocainehydrochloride as an active ingredient.
Claim 4
Dependent Claim
19 words
A crosslinked hydrogel as defined in claim 1 containing up to 0.5% hydrocortisone by weight as the active ingredient.
Claim 5
Dependent Claim
16 words
A crosslinked hydrogel as defined in claim 3 containing from about 0.0% to about 2.0% menthol.
Claim 6
Dependent Claim
19 words
A crosslinked hydrogel as defined in claim 1 further comprising a scrim supporting said gel in a predetermined shape.
Claim 7
Dependent Claim
80 words
A crosslinked hydrogen containing an active ingredient for transdermal medical application comprising: (a) water; (b) an active ingredient selected from the class of menthol, methyl salicylate, lidocainehydrochloride or hydrocortisone; (c) aluminum acetate, a crosslinking agent providing ionic conductivity to said hydrogel, in a quantity of about 0.1% to about 0.5% by weight such that hydrogel has a resistance of less than 10,000 ohms per linear centimeter; and (d) carboxymethylcellulose in an amount of between about 1.1% to 1.7% by weight.
Claim 8
Dependent Claim
80 words
A crosslinked hydrogen containing an active ingredient for transdermal medical application comprising: (a) water; (b) an active ingredient selected from the class of menthol, methyl salicylate, lidocainehydrochloride or hydrocortisone; (c) aluminum acetate, a crosslinking agent providing ionic conductivity to said hydrogel, in a quantity of about 0.1% to about 0.5% by weight such that hydrogel has a resistance of less than 10,000 ohms per linear centimeter; and (d) carboxymethylcellulose in an amount of between about 1.1% to 1.7% by weight.
Claim 9
Dependent Claim
19 words
A crosslinked hydrogel as defined in claim 6 containing from about 3% to about 8% by weight methyl salicylate.
Claim 10
Dependent Claim
16 words
A crosslinked hydrogel as defined in claim 6 containing up to about 1.0% by weight hydrocortisone.
Claim 11
Dependent Claim
14 words
A crosslinked hydrogel as defined in claim 6 containing up to about 4% lidocainehydrochloride.
Claim 12
Dependent Claim
17 words
A crosslinked hydrogel as defined in claim 6 containing between 1.4 g and 1.7 g of carboxymethylcellulose.
References Cited (Backward Citations)
US4349470A
Cited
US4853227A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-12-02 | 1995-06-03 | 1995-12-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-12-02 | 1999-06-03 | 1999-12-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-12-02 | 2003-06-03 | 2003-12-03 | $7700.00 | Window Closed / Lapsed |